Log inTry free

Braveheart Bio (BRVE) stock

Market cap $1.9B

$19.79
-7.31%

Market closed. Prices as of Tuesday's close.

Quality Score
-1
Poor
In its industry
#166of 308
Biotech

New listing, trading since Aug 6, 2026. 43 trading days so far, so 5 of the 14 checks wait for more history.

Next2026“…Phase 3 study in obstructive HCM (“oHCM”), and we are on track to dose the first patient this year…”Trial start · 8-K, Sep 8

Follow BRVE's trial news. Pro members can get an alert when Braveheart Bio files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when BRVE files news on its trialSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Holding it back

165.1% more shares than a year ago.

1 more reason behind BRVE's -1, for Pro members

What's next for BRVE, and how long its cash lasts

From Braveheart Bio’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2026“Sites are being activated and patients are screening for our LIONHEART-HCM Phase 3 study in obstructive HCM (“oHCM”), and we are on track to dose the first patient this year.”Trial start · 8-K, Sep 8

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
LIONHEART-HCMPhase 3 · Recruiting · 210 people · main data estimated Oct 2028 · NCT07755904

For Pro members: 1 more milestone and 2 filings.

Cash runway Jun 30 balance sheet

$123M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's own estimate is “into 2029” (8-K, Sep 8). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration of its own or at-the-market program on file in the last three years.

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Erez Chimovits bought 1,940,000 shares on Aug 7. 7 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Travis Murdoch buys or sells

For Pro members: every trade, and Travis Murdoch’s 3 filings and quotes.

Get an optional alert when BRVE files news on its trialSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 112 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why BRVE scores -1

PoorTrending down, 0 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • −2Dilution 165.1% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.
  • +3Insider trades Travis Murdoch (CEO and President) bought $1.5M on Aug 7; 6 insiders buying
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Chart checks, Long-term trend, Run-up, Size, Profit, Growth, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on BRVE and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 12:33 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Thu Nov 12, after the close

After its last report it closed -1.7%.

Fri Aug 6: One year since its IPOListed Aug 6, 2026 at $18.

What would turn BRVE's score around: 4 things, for Pro members

Alert me when BRVE's Quality Score turns up

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on BRVE and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Nothing is firing on BRVE right now

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on BRVE, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

How BRVE ranks in Biotech

BRVE is #166 of 308 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does BRVE report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 36 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Sep 8, 2026After close-0.9%-1.7%-9.2%

The gap is the next open against the close before the report; the reaction is where that session closed. BRVE closed higher after 0 of its last 1. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

Who is trading BRVE

BRVE insider trades

8 insiders bought $89.2M across 9 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyAH BIO Fund IV, L.P.$19.8M10% ownerat $18.00 on Aug 7, filed Aug 11
All 9 insider filings on BRVE from the last six months, for Pro members.Get in free →

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

BRVE's officers and directors

Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.

See insider trades by person

About Braveheart Bio

Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

San Francisco, CAbraveheart.bio

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of BRVE's score, with the points and the reason
  • All 14 checks on BRVE and on all 3,283 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on BRVE
BreakawayAug 11AH BIO Fund IV, L.P. bought BRVE$19.8M at $18.00, filed Aug 11

What a filing on BRVE would have sent. Alerts are optional.

See all 14 checks on BRVESee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.